Completed PHASE3 INTERVENTIONAL 3-arm NCT02149121

PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis (rituximab)

A Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety Between CT-P10, Rituxan and MabThera in Patients With Rheumatoid Arthritis

Sponsor: Celltrion

Conditions Rheumatoid Arthritis

Interventions CT-P10 MabThera Rituxan

Updated 8 times since 2017 Last updated: Nov 18, 2021 Started: Aug 31, 2014 Primary completion: Jan 31, 2016 Completion: Jan 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02149121, this PHASE3 trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by Celltrion, it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jan 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jun 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jan 2017 — Jun 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celltrion

Data source: Celltrion

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.